ArticleChinese medicine2026
Unraveling the potential mechanisms of Xiaochaihu decoction alleviates metabolic associated fatty liver disease (MAFLD) by integrated transcriptomics, metabolomics, and network pharmacology.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global pattern and evolution of PPARγ in breast cancer: a 25-Year bibliometric and visualized knowledge map analysis.Frontiers in oncology · 2026Pooled it
- Interpreting the Black Box: Interpretable Machine Learning and Systems Pharmacology in Small-Molecule Therapeutics.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMetabolic associated fatty liver disease (MAFLD) has currently emerged as the predominant form of chronic liver diseases nowadays, with a high morbidity. Nevertheless, the general remission rate of current treatments for MAFLD remains unsatisfactory. The traditional Chinese medicine formulation Xiaochaihu decoction (XCHD) alleviates triglyceride (TG) and total cholesterol (TC) in patients with fatty liver disease, but the precise mechanisms remain to be determined. PURPOSE: This study aimed to investigate the effects and underlying mechanisms of XCHD on MAFLD.
methodsThe components of XCHD and XCHD-containing serum were characterized by UPLC/MS. High-fat diet and glucose-fructose water-induced MAFLD model in mice was established to evaluate the effects of XCHD. Non-targeted metabolomics, RNA-sequencing, and Network pharmacology were performed and integrated in the mice liver. Molecular biology experiments, like Western blot, were taken to investigate its potential mechanisms. Finally, the effects of PPARγ, perilipin 2 (PLIN2), and perilipin 3 (PLIN3) were detected by over-expressed PPARγ or suppressed PPARγ.
resultsXCHD markedly alleviates MAFLD by reducing lipid droplets, TC, and TG accumulation in MAFLD mice and free fatty acid induced HepG2 and AML12 cells. Non-targeted metabolomics suggested that XCHD reduced hepatic lysophospholipid, and RNA-sequencing revealed that the underlying mechanism would be related to lipid droplet formation. Molecular biology experiments indicated that XCHD decreased PLIN2 and PLIN3 in vivo and in vitro. Network pharmacology analysis revealed that the mechanism of XCHD against MAFLD involves the PPARγ signaling pathway. Molecular biology experiments indicated that XCHD decreased PPARγ in vivo and in vitro. Overexpression of PPARγ indicated that XCHD exert regulatory effects through PPARγ-mediated inhibition of PLIN2 and PLIN3. However, the inhibitory effects of XCHD on PLIN2 and PLIN3 are not solely dependent on this pathway.
conclusionXCHD alleviates MAFLD by decreasing lysophospholipid, regulating liver lipid droplets formation, and targeting PLIN2/PLIN3. PPARγ was one of the cross in for PLIN2/PLIN3 pathway, which provides novel insights for MAFLD therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.